Aurobindo Pharma — 360° view

Aurobindo Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹10,263 crore and net profit of ₹1,124 crore for the September 2026 quarter.

Aurobindo Pharma (NSE: AUROPHARMA) closed at ₹1,799.00 on 20 Nov 2026, up 49.0% over the past year. Its market capitalisation is ₹1,03,510 crore and it trades at 25.5 times earnings.

Share price
₹1,799.00 (20 Nov 2026)
Market cap
₹1,03,510 Cr (20 Nov 2026)
P/E
25.51 (20 Nov 2026)
Revenue
₹10,263 Cr (September 2026 quarter)
Net profit
₹1,124 Cr (September 2026 quarter)
ROCE
12.9% (FY26)
ROE
10.1% (FY26)
Book value
₹685 (FY26)
Dividend yield
0.39% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,859.90 / ₹1,106.00 (20 Nov 2026)
1-year return
49.0% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: AUROPHARMA

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.